Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011093358> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W3011093358 abstract "TPS7606 Background: Stage IIIA NSCLC constitutes 30% of all NSCLC patients (pts). The most powerful prognostic factor that has been identified in this stage is clearance of mediastinal lymph nodes and pathologic complete response (pCR). A pCR is obtained in 5-15% of pts with a significant survival prolongation. The identification of molecular biomarkers, such as excision repair cross-complementation 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), and thymidylate synthase (TS), may predict response to CT. Similarly, EGFR mutations may predict response to EGFR inhibitors. Methods: CONTEST, a multicenter (19 Italian centers), randomized (2:1) 2-arm phase II study, recruits pts with resectable stage IIIA (N2) NSCLC. Pts will be randomized to receive before resection either standard CT with Cisplatin (CDDP) 75 mg/m 2 + Docetaxel (Doc) 75 mg/m 2 on day (d) 1 q 21 d for 3 cycles (cys) or customized therapy using predetermined values for ERCC1, RRM1, TS, and EGFR mutations. The choices of customized arms are as follows: -EGFR+: Gefitinib 250 mg/d for 8 weeks. -EGFR-/non-squamous (NS)/TS-/ERCC1-: CDDP 75 mg/m 2 + Pemetrexed 500 mg/m 2 d 1 q 21 d for 3 cys. -EGFR-/squamous (S) or NS TS+/ERCC1-/RRM1+: CDDP 75 mg/m 2 + Doc 75 mg/m 2 d 1 q 21 d for 3 cys. -EGFR-/S or NS TS+/ERCC1-/RRM1-: CDDP 75 mg/m 2 d 1+ Gemcitabine (Gem) 1250 mg/m 2 d 1,8 q 21 d for 3 cys. -EGFR-/S or NS TS+/ERCC1+/RRM1+: Doc 75 mg/m 2 d 1 + Vinorelbine 20 mg/m 2 d 1,8 q 21 d for 3 cys. -EGFR-/S or NS TS+/ERCC1+/RRM1-: Doc 40 mg/m 2 y 1, 8 + Gem 1200 mg/m 2 d 1,8 q 21 d for 3 cys. The primary end point will be obtained by comparing the pCR in all randomized pts based on treatment arm. Because pCR is a surrogate endpoint and given the expected proportion of pCR's in the control group pc= 5%, the minimal clinically worthwhile effect of this customized treatment is an increase in this proportion to 20%. To detect such an effect at the 0.05 (1-sided) significance level with 80% power, a total of 168 pts will be enrolled. This study is open for accrual; further details can be found on ClinicalTrials.gov (NCT01784549). Funded by Italian Ministry of Health – RF 2009-1530324. Clinical trial information: NCT01784549." @default.
- W3011093358 created "2020-03-23" @default.
- W3011093358 creator A5013441605 @default.
- W3011093358 creator A5031589731 @default.
- W3011093358 creator A5032477448 @default.
- W3011093358 creator A5035375963 @default.
- W3011093358 creator A5043174098 @default.
- W3011093358 creator A5080816334 @default.
- W3011093358 creator A5083059057 @default.
- W3011093358 creator A5086247944 @default.
- W3011093358 creator A5086719405 @default.
- W3011093358 date "2013-05-20" @default.
- W3011093358 modified "2023-09-25" @default.
- W3011093358 title "A multicenter phase II randomized study of customized neoadjuvant therapy versus standard chemotherapy (CT) in non-small cell lung cancer (NSCLC) patients with resectable stage IIIA(N2) disease (CONTEST trial)." @default.
- W3011093358 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.tps7606" @default.
- W3011093358 hasPublicationYear "2013" @default.
- W3011093358 type Work @default.
- W3011093358 sameAs 3011093358 @default.
- W3011093358 citedByCount "0" @default.
- W3011093358 crossrefType "journal-article" @default.
- W3011093358 hasAuthorship W3011093358A5013441605 @default.
- W3011093358 hasAuthorship W3011093358A5031589731 @default.
- W3011093358 hasAuthorship W3011093358A5032477448 @default.
- W3011093358 hasAuthorship W3011093358A5035375963 @default.
- W3011093358 hasAuthorship W3011093358A5043174098 @default.
- W3011093358 hasAuthorship W3011093358A5080816334 @default.
- W3011093358 hasAuthorship W3011093358A5083059057 @default.
- W3011093358 hasAuthorship W3011093358A5086247944 @default.
- W3011093358 hasAuthorship W3011093358A5086719405 @default.
- W3011093358 hasConcept C126322002 @default.
- W3011093358 hasConcept C126838900 @default.
- W3011093358 hasConcept C143998085 @default.
- W3011093358 hasConcept C146357865 @default.
- W3011093358 hasConcept C151730666 @default.
- W3011093358 hasConcept C2776256026 @default.
- W3011093358 hasConcept C2776694085 @default.
- W3011093358 hasConcept C2779177807 @default.
- W3011093358 hasConcept C71924100 @default.
- W3011093358 hasConcept C81729549 @default.
- W3011093358 hasConcept C86803240 @default.
- W3011093358 hasConceptScore W3011093358C126322002 @default.
- W3011093358 hasConceptScore W3011093358C126838900 @default.
- W3011093358 hasConceptScore W3011093358C143998085 @default.
- W3011093358 hasConceptScore W3011093358C146357865 @default.
- W3011093358 hasConceptScore W3011093358C151730666 @default.
- W3011093358 hasConceptScore W3011093358C2776256026 @default.
- W3011093358 hasConceptScore W3011093358C2776694085 @default.
- W3011093358 hasConceptScore W3011093358C2779177807 @default.
- W3011093358 hasConceptScore W3011093358C71924100 @default.
- W3011093358 hasConceptScore W3011093358C81729549 @default.
- W3011093358 hasConceptScore W3011093358C86803240 @default.
- W3011093358 hasLocation W30110933581 @default.
- W3011093358 hasOpenAccess W3011093358 @default.
- W3011093358 hasPrimaryLocation W30110933581 @default.
- W3011093358 isParatext "false" @default.
- W3011093358 isRetracted "false" @default.
- W3011093358 magId "3011093358" @default.
- W3011093358 workType "article" @default.